CVE-2026-52866: Apollo Pharmacy Blood Glucose Monitoring System (Model No. APG-01 BT) · Missing Authorization
Affects Apollo Pharmacy Blood Glucose Monitoring System (Model No. APG-01 BT)Source CVE Database V5
Not known to be exploited · CVSS 6.5 Medium.
Data as of 1 Nov 2026, 22:58 UTC
- EPSS
- 0.3% chance of exploitation in 30 days – higher than 28% of CVEsExploit Prediction Scoring System: the likelihood attackers will use this flaw soon.
CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:HExploitation evidence
Disclosed: evidence found.
CVE published 18 Jun 2026
Detectable: no evidence on record.
No public nuclei template indexed
Weaponized: no evidence on record.
No public exploit code indexed in Metasploit or Exploit-DB
Exploited in the wildExploited: no evidence on record.
Not in CISA KEV and no source reports exploitation
Observed by OffSeq MirageSeen by Mirage: no evidence on record.
No attack traffic recorded by OffSeq Mirage sensors
A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 1 Nov 2026.
What to do
Affected software
| Product | Affected | Fixed in |
|---|---|---|
| Apollo PharmacyBlood Glucose Monitoring System (Model No. APG-01 BT) | Affected
| Fixed in– |
AI-suggested
Users should monitor vendor advisories for updates. As the device is not a cloud service, remediation depends on vendor-provided firmware updates. Until a fix is released, limiting physical proximity to trusted users and devices may reduce risk.
Description
An attacker within BLE communication range can monopolize the device's only available BLE connection slot, preventing legitimate users or applications from establishing a connection.
References
- apollopharmacy.in/contact-us (opens in a new tab)
- cisa.gov/news-events/news/understanding-bluetooth-technology (opens in a new tab)
- cisa.gov/news-events/ics-medical-advisories/icsma-26-169-01 (opens in a new tab)
- github.com/cisagov/CSAF/blob/develop/csaf_files/OT/white/2026/icsma-26-169-01.json (opens in a new tab)